ArticleJMIR diabetes2025
Prevalence and Risk Factors of Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes Mellitus at a Tertiary Center in Saudi Arabia: Cross-Sectional Questionnaire Study.
Article in JMIR diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The escalating rates of obesity and type 2 diabetes mellitus (T2DM) in Saudi Arabia highlight the impending burden of metabolic dysfunction-associated steatotic liver disease (MASLD) and nonalcoholic steatohepatitis. Objective: This study aimed to identify MASLD among patients with T2DM at King Saud Medical City family medicine clinics, Riyadh, and explore associated factors to facilitate early intervention and prevention strategies. Methods: This cross-sectional study identified patients with T2DM who attended King Saud Medical City, Riyadh, underwent an abdominal ultrasound, and were diagnosed with MASLD. The study data were collected by a peer-reviewed validated data extraction sheet and analyzed by SPSS (version 26.0; IBM Corp). Results: Our study included 292 participants, with 47.3% (n=138) males and 52.7% (n=154) females. Notably, the prevalence of MASLD was 54.5% (n=159). Prevalent comorbidities included dyslipidemia (218/292, 74.7%) and hypertension (209/292, 71.6%). Most participants were nonsmokers (218/292, 74.7%). Higher waist circumference was significantly associated with MASLD (P=.02), with >80 cm among females (85/141, 60.3%) and >94 cm among males (60/141, 54.5%) affected across different stages of MASLD. Obesity (BMI>30 kg/m2) also significantly correlated with MASLD (P<.001). Individuals taking aspirin had half the odds of MASLD development (odds ratio [OR] 0.523, 95% CI 0.331-0.844; P=.007). Biochemical analysis revealed significant associations between MASLD and elevated alanine aminotransferase (P=.009), aspartate aminotransferase (P=.01), and homeostatic model assessment of insulin resistance (P=.001). Total cholesterol (P=.01), triglycerides (P=.03), and low-density lipoprotein (P=.04) were significantly elevated in patients with MASLD. Insulin exhibited a significant positive correlation with MASLD (r=0.24; P=.001). Glucose levels showed no significant association (r=0.03; P=.63). Conclusions: Our study highlights significant associations between MASLD and various factors, including waist circumference, obesity, and certain biochemical markers. Furthermore, the protective effect of aspirin against MASLD warrants further investigation. These findings underscore the importance of early intervention and targeted preventive strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.